颌面部非霍奇金淋巴瘤33例化疗疗效观察
2016-05-24王瑜
王瑜

【摘要】 目的 观察并研究通过化疗治疗颌面部非霍奇金淋巴瘤的疗效。方法 33例颌面部非霍奇金淋巴瘤首诊患者, 给予以化疗为主的综合治疗, 采用COP、CHOP方案为主的规范性治疗方案, 观察治疗效果。结果 33例患者患病区及分期分析, 颈部区20例, 颌下区8例, 舌根部1例, 腭部1例, 下唇1例, 颊面部1例, 腮腺1例;Ⅰ期3例, Ⅱ期13例, Ⅲ期12例, Ⅳ期5例。治疗后死亡8例。颈部区非霍奇金淋巴瘤的患病人数最多;舌根部的死亡率(100.0%)最高;Ⅳ期非霍奇金淋巴瘤的死亡比例(62.5%)最高。结论 颈部区非霍奇金淋巴瘤的患病人数最多;舌根部的死亡率最高;Ⅳ期非霍奇金淋巴瘤的死亡比例最高。
【关键词】 颌面部非霍奇金淋巴瘤;化疗;病理分期
DOI:10.14163/j.cnki.11-5547/r.2016.15.012
【Abstract】 Objective To observe curative effect by chemotherapy for maxillofacial non-hodgkin's lymphoma. Methods A total of 33 maxillofacial non-hodgkin's lymphoma patients received comprehensive treatment by chemotherapy and conventional therapy by COP and CHOP regimen. Curative effects were observed. Results Lesion and pathological stage analysis in 33 cases showed 20 nick cases, 8 submaxillay cases, 1 tongue root case, 1 palatine case, 1 lower lip case, 1 buccal facial case, 1 parotid gland case; and 3 stage Ⅰ cases, 13 stage Ⅱ cases, 12 stage Ⅲ cases, and 5 stage Ⅳ cases. There were 8 death cases after treatment. Maxillofacial non-hodgkin's lymphoma in nick had the highest patient number, mortality of tongue root (100.0%) is the highest, and mortality of stage Ⅳ (62.5%) is the highest. Conclusion Maxillofacial non-hodgkin's lymphoma in nick had the highest patient number, mortality of tongue root is the highest, and mortality of stage Ⅳ is the highest.
【Key words】 Maxillofacial non-hodgkin's lymphoma; Chemotherapy; Pathological stage
淋巴瘤是最常见的淋巴造血系统恶性肿瘤, 是指淋巴结和结外部位淋巴组织的免疫细胞肿瘤, 由淋巴细胞或组织细胞发生恶变后产生。世界卫生组织(WHO)将淋巴瘤分为霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)。在口腔颌面部恶性肿瘤中, 淋巴瘤的病例构成占第二位[1]。近年来我国颌面部非霍奇金淋巴瘤的发生率逐年上升趋势明显, 且早期无明显的特殊体征, 误诊与漏诊率较高, 预后较差。本科对33例颌面部非霍奇金淋巴瘤患者的化疗疗效进行了研究, 现将研究结果报告如下。
1 资料与方法
1. 1 一般资料 选择2013年6月~2015年6月本科颌面部非霍奇金淋巴瘤首诊患者共33例, 男22例, 女11例, 年龄13~57岁, 平均年龄37岁, 病程1个月~8年。临床表现为鼻塞14例, 低热9例, 颈部肿块18例, 涕血19例, 耳鸣听力下降8例, 体表淋巴结肿大7例。……
